Runnymede Capital Advisors, Inc. Amgen Inc Transaction History
Runnymede Capital Advisors, Inc.
- $114 Billion
- Q4 2024
A detailed history of Runnymede Capital Advisors, Inc. transactions in Amgen Inc stock. As of the latest transaction made, Runnymede Capital Advisors, Inc. holds 175 shares of AMGN stock, worth $51,969. This represents 0.04% of its overall portfolio holdings.
Number of Shares
175Holding current value
$51,969% of portfolio
0.04%Shares
1 transactions
Others Institutions Holding AMGN
# of Institutions
3,124Shares Held
417MCall Options Held
8.84MPut Options Held
6.55M-
Vanguard Group Inc Valley Forge, PA52.7MShares$15.7 Billion0.25% of portfolio
-
Black Rock Inc. New York, NY46MShares$13.7 Billion0.33% of portfolio
-
State Street Corp Boston, MA29.3MShares$8.71 Billion0.39% of portfolio
-
Morgan Stanley New York, NY14.7MShares$4.36 Billion0.35% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA13.2MShares$3.92 Billion0.65% of portfolio
About AMGEN INC
- Ticker AMGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 534,931,008
- Market Cap $159B
- Description
- Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...